{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T10:46:28Z","timestamp":1773571588283,"version":"3.50.1"},"reference-count":22,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s40425-018-0471-2","type":"journal-article","created":{"date-parts":[[2018,12,22]],"date-time":"2018-12-22T01:02:26Z","timestamp":1545440546000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Infliximab for treatment-refractory transverse myelitis following immune therapy and radiation"],"prefix":"10.1136","volume":"6","author":[{"given":"Victoria A.","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel R.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory A.","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6006-0126","authenticated-orcid":false,"given":"David E.","family":"Piccioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,12,22]]},"reference":[{"issue":"1","key":"471_CR1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nrclinonc.2013.208","volume":"11","author":"CG Drake","year":"2014","unstructured":"Drake CG, Lipson EJ, Brahmer JR. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol. 2014;11(1):24\u201337 \n                    https:\/\/doi.org\/10.1038\/nrclinonc.2013.208\n                    \n                  .","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"471_CR2","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/cam4.371","volume":"4","author":"LH Camacho","year":"2015","unstructured":"Camacho LH. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations. Cancer Med. 2015;4(5):661\u201372 \n                    https:\/\/doi.org\/10.1002\/cam4.371\n                    \n                  .","journal-title":"Cancer Med"},{"issue":"17","key":"471_CR3","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of Immune-Related Adverse Events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714\u201368 \n                    http:\/\/ascopubs.org\/doi\/10.1200\/JCO.2017.77.6385\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"1","key":"471_CR4","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"Puzanov I, Diab A, Abdallah K, Bingham CO, Brogdon C, Dadu R, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group. J Immunother Cancer. 2017;5(1):95 \n                    https:\/\/doi.org\/10.1186\/s40425-017-0300-z\n                    \n                  .","journal-title":"J Immunother Cancer"},{"key":"471_CR5","unstructured":"Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Davies M, et al. Management of Immunotherapy-Related Toxicities (immune checkpoint inhibitor-related toxicities) version 2.2018. NCCN. 2018 [updated 2018 Aug 19]. \n                    https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/immunotherapy.pdf"},{"issue":"1\u20132","key":"471_CR6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.clsc.2017.07.001","volume":"2","author":"R Mir","year":"2017","unstructured":"Mir R, Shaw HM, Nathan PD. Immunosuppressive agents and their role in managing immunotherapy toxicities in melanoma. Clin Ski Cancer. 2017;2(1\u20132):18\u201323 \n                    https:\/\/doi.org\/10.1016\/j.clsc.2017.07.001\n                    \n                  .","journal-title":"Clin Ski Cancer"},{"issue":"12","key":"471_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/pbc.26642","volume":"64","author":"SJ Rotz","year":"2017","unstructured":"Rotz SJ, Leino D, Szabo S, Mangino JL, Turpin BK, Pressey JG. Severe cytokine release syndrome in a patient receiving PD-1-directed therapy. Pediatr Blood Cancer. 2017;64(12):1\u20134 \n                    https:\/\/doi.org\/10.1002\/pbc.26642\n                    \n                  .","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"471_CR8","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1136\/annrheumdis-2017-211560","volume":"76","author":"ST Kim","year":"2017","unstructured":"Kim ST, Tayar J, Trinh VA, Suarez-Almazor M, Garcia S, Hwu P, et al. Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. Ann Rheum Dis. 2017;76(12):2061\u20134 \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2017-211560\n                    \n                  .","journal-title":"Ann Rheum Dis"},{"issue":"0","key":"471_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1078155217745144","volume":"0","author":"CRG Stroud","year":"2017","unstructured":"Stroud CRG, Hegde A, Cherry C, Naqash AR, Sharma N, Addepalli S, et al. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J Oncol Pharm Pract. 2017;0(0):1\u20137 \n                    https:\/\/doi.org\/10.1177\/1078155217745144\n                    \n                  .","journal-title":"J Oncol Pharm Pract"},{"issue":"6","key":"471_CR10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s11912-018-0690-1","volume":"20","author":"A Asnani","year":"2018","unstructured":"Asnani A. Cardiotoxicity of immunotherapy: incidence, diagnosis, and Management. Curr Oncol Rep. 2018;20(6):44 \n                    https:\/\/doi.org\/10.1007\/s11912-018-0690-1\n                    \n                  .","journal-title":"Curr Oncol Rep"},{"issue":"11","key":"471_CR11","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1007\/s10620-008-0641-z","volume":"54","author":"RL Johnston","year":"2009","unstructured":"Johnston RL, Lutzky J, Chodhry A, Barkin JS. Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab. Dig Dis Sci. 2009;54(11):2538\u201340 \n                    https:\/\/doi.org\/10.1007\/s10620-008-0641-z\n                    \n                  .","journal-title":"Dig Dis Sci"},{"issue":"3","key":"471_CR12","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1089\/cbr.2008.0607","volume":"24","author":"DR Minor","year":"2009","unstructured":"Minor DR, Chin K, Kashani-sabet M. Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis. Cancer Biother Radiopharm. 2009;24(3):321\u20135 \n                    https:\/\/doi.org\/10.1089\/cbr.2008.0607\n                    \n                  .","journal-title":"Cancer Biother Radiopharm"},{"issue":"5","key":"471_CR13","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1136\/bjo.2008.150961","volume":"94","author":"P Doctor","year":"2010","unstructured":"Doctor P, Sultan A, Syed S, Christen W, Bhat P, Foster CS. Infliximab for the treatment of refractory scleritis. Br J Ophthalmol. 2010;94(5):579\u201383 \n                    https:\/\/doi.org\/10.1136\/bjo.2008.150961\n                    \n                  .","journal-title":"Br J Ophthalmol"},{"issue":"16","key":"471_CR14","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1200\/JCO.2017.76.2229","volume":"36","author":"JJ Luke","year":"2018","unstructured":"Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, et al. Safety and clinical activity of Pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors. J Clin Oncol. 2018;36(16):1611\u20138 \n                    http:\/\/ascopubs.org\/doi\/10.1200\/JCO.2017.76.2229\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"471_CR15","doi-asserted-by":"crossref","unstructured":"McBride SM, Sherman EJ, Tsai CJ, Baxi SS, Aghalar J, Eng J, et al. A phase II randomized trial of nivolumab with stereotactic body radiotherapy (SBRT) versus nivolumab alone in metastatic (M1) head and neck squamous cell carcinoma (HNSCC) [abstract]. J Clin Oncol. 2018;36(suppl; abstr 6009). \n                    http:\/\/abstracts.asco.org\/214\/AbstView_214_223041.html\n                    \n                  .","DOI":"10.1200\/JCO.2018.36.15_suppl.6009"},{"key":"471_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","volume":"73","author":"S Cuzzubbo","year":"2017","unstructured":"Cuzzubbo S, Javeri F, Tissier M, Roumi A, Barlog C, Doridam J, et al. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer. 2017;73:1\u20138 \n                    https:\/\/doi.org\/10.1016\/j.ejca.2016.12.001\n                    \n                  .","journal-title":"Eur J Cancer"},{"key":"471_CR17","doi-asserted-by":"crossref","unstructured":"Scott TF, Frohman EM, De Seze J, Gronseth GS, Weinshenker BG. Evidence-based guideline: Clinical evaluation and treatment of transverse myelitis. Neurology 2011;77(24):2128 LP \u2013 2122134. http:\/\/n.neurology.org\/content\/77\/24\/2128","DOI":"10.1212\/WNL.0b013e31823dc535"},{"key":"471_CR18","doi-asserted-by":"crossref","unstructured":"Garcia CA, El-Ali A, Rath TJ, et al. Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases. J Immunother Cancer. 2018;6(83) \n                    http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6117978\/\n                    \n                  .","DOI":"10.1186\/s40425-018-0393-z"},{"issue":"3\u20134","key":"471_CR19","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/0360-3016(78)90144-X","volume":"4","author":"JS Abbatucci","year":"1978","unstructured":"Abbatucci JS, Delozier T, Quint R, Roussel ABD. Radiation myelopathy of the cervical spinal cord: time, dose and volume factors. Int J Radiat Oncol Biol Phys. 1978;4(3\u20134):239\u201348 \n                    https:\/\/doi.org\/10.1016\/0360-3016(78)90144-X\n                    \n                  .","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3 Suppl 1","key":"471_CR20","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1016\/j.ijrobp.2009.04.095","volume":"76","author":"JP Kirkpatrick","year":"2010","unstructured":"Kirkpatrick JP, Van der Kogel AJ, Schultheiss TE. Radiation dose-volume effects in the spinal cord. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl 1):S42\u20139 \n                    https:\/\/doi.org\/10.1016\/j.ijrobp.2009.04.095\n                    \n                  .","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"471_CR21","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/0360-3016(92)90943-C","volume":"30","author":"CS Wong","year":"1994","unstructured":"Wong CS, Van Dyk J, Milosevic MLN. Radiation myelopathy following single course of radiotherapy and retreatment. Int J Radiat Oncol Biol Phys. 1994;30(3):575\u201381 \n                    https:\/\/doi.org\/10.1016\/0360-3016(92)90943-C\n                    \n                  .","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"471_CR22","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/sc.2015.43","volume":"53","author":"CS Wong","year":"2015","unstructured":"Wong CS, Fehlings MG, Sahgal A. Pathobiology of radiation myelopathy and strategies to mitigate injury. Spinal Cord. 2015;53:574\u201380 \n                    https:\/\/doi.org\/10.1038\/sc.2015.43\n                    \n                  .","journal-title":"Spinal Cord"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-018-0471-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-018-0471-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-018-0471-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:43:19Z","timestamp":1601055799000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-018-0471-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["471"],"URL":"https:\/\/doi.org\/10.1186\/s40425-018-0471-2","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"16 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication was obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"153"}}